Moderna Cancer Vaccines Patent Grant
Summary
The USPTO has granted patent US12582609B2 to ModernaTX, Inc. for cancer ribonucleic acid (RNA) vaccines. The patent covers cancer RNA vaccines, methods of use, and compositions. This grant is a routine notification of intellectual property protection.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582609B2 to ModernaTX, Inc. The patent, titled "Cancer vaccines," relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using and compositions comprising these vaccines. The filing date for this application was October 21, 2016, and the patent was granted on March 24, 2026, with 36 claims.
This patent grant represents the formal recognition of intellectual property for Moderna's cancer vaccine technology. For compliance officers, this is primarily an informational update regarding a competitor's or partner's intellectual property status. There are no immediate compliance obligations or actions required for regulated entities based solely on this patent grant, other than awareness of the IP landscape.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cancer vaccines
Grant US12582609B2 Kind: B2 Mar 24, 2026
Assignee
ModernaTX, Inc.
Inventors
Nicholas Valiante, Tal Zaks, Eric Yi-Chun Huang
Abstract
The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
CPC Classifications
A61K 39/0011 A61K 2039/53 A61K 39/001114 A61K 9/10 A61K 9/5123 A61K 2039/545 A61K 2039/55588 A61P 35/00
Filing Date
2016-10-21
Application No.
15769710
Claims
36
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.